课题基金 / 基金详情

Applying Item Response Theory to Improve Patient Reported Outcome Use in Dermatology Clinical Practice

Applying Item Response Theory to Improve Patient Reported Outcome Use in Dermatology Clinical Practice
应用项目反应理论改善皮肤科临床实践中患者报告的结果使用
批准号:
10655603
负责人:
John Barbieri
金额:
$17.39万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2027-06-30

项目摘要

项目成果

John Barbieri的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Research: While effective measurement of the patient’s perspective on their illness and its treatment provides complimentary information to objective disease severity, patient-reported outcomes capturing the lived experience of chronic inflammatory skin disease are rarely used in routine dermatology practice. Item response theory techniques can enable more efficient administration of patient-reported outcomes in the clinic, which can address barriers such as time to administer these measures. The purpose of this study is to 1. prioritize the outcome domains that are most meaningful to individuals with chronic inflammatory skin diseases such as acne, psoriasis, and atopic dermatitis; 2. evaluate the content validity of a novel Patient-Reported Outcomes Measurement Information System (PROMIS) profile measuring these domains; 3. field test and evaluate the validity of a novel PROMIS profile to capture the lived experience of chronic inflammatory skin disease. The overall objectives of this K23 award proposal are to improve the care of patients with chronic inflammatory skin diseases by developing a practical patient-reported outcome to measure the lived experience of these skin diseases, which will enable increased use of patient-reported outcomes in routine clinical care. Candidate: Dr. Barbieri’s long-term career goal is to become an independent, patient-oriented physician- scientist, with a focus on chronic inflammatory skin diseases, patient-reported outcomes, and health services research. His prior training has provided him with a foundational background in these areas. Environment: During the award period Dr. Barbieri will devote 80% of his time to clinical research and 20% to the clinical care of patients with chronic inflammatory skin disease such as acne, atopic dermatitis, and psoriasis. Dr. Margolis and Dr. Pusic, the candidate’s primary mentors, have directly supervised the training of numerous successful junior faculty members and Dr. Barbieri will benefit from his experience and enthusiasm for cultivating the careers of junior scientists. The Brigham and Women’s Hospital offers a rich training environment, including resources and expertise available in the Clinical Unit for Research Innovation and Trials (CUReIT) and Patient-Reported Outcomes, Value & Experience (PROVE) Center. Combined with the knowledge and expertise available in the Department of Dermatology and in Dr. Margolis’s and Dr. Pusic’s labs, these opportunities will provide an unparalleled opportunity to begin a career as a physician scientist. Career Development: With the support of his advisory committee, Dr. Barbieri’s training will focus on advanced psychometric techniques and qualitative research to develop a strong knowledge base with respect to patient-reported outcome development and validation. Completion of the proposed research and career development plan will give Dr. Barbieri the knowledge and skills to achieve scientific independence, transition to a tenure track faculty position, and build a strong foundation for a career in patient-oriented clinical research.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
Effectiveness of spironolactone for women with acne vulgaris (SAFA) trial: a critically appraised topic.
螺内酯对女性寻常痤疮 (SAFA) 试验的有效性:一个受到严格评价的话题。
DOI: 10.1093/bjd/ljad270
发表时间: 2023
期刊: The British journal of dermatology
影响因子: --
作者: [Shields,Ali, Barbieri,JohnS]
通讯作者: Barbieri,JohnS
Isotretinoin exposure does not appear to be associated with risk of adverse male sexual health outcomes in acne patients.
异维A酸暴露似乎与痤疮患者男性性健康不良后果的风险无关。
DOI: 10.1111/ijd.16865
发表时间: 2024
期刊: International journal of dermatology
影响因子: 3.6
作者: [Thang,ChristopherJ, Garate,David, Golovko,George, Barbieri,JohnS]
通讯作者: Barbieri,JohnS
The role of oral nutraceuticals as adjunctive therapy to reduce side effects from isotretinoin: A systematic review.
口服营养保健品作为辅助治疗减少异维A酸副作用的作用:系统评价。
DOI: 10.1016/j.jaad.2023.10.037
发表时间: 2024
期刊: Journal of the American Academy of Dermatology
影响因子: 13.8
作者: [Shields,Ali, Ly,Sophia, Wafae,Bruna, Chang,Yu-Feng, Manjaly,Priya, Archila,Marjorie, Heinrich,Christina, Drake,Lara, Mostaghimi,Arash, Barbieri,JohnS]
通讯作者: Barbieri,JohnS
Temporal Trends in the Use of Systemic Medications for Acne From 2017 to 2020.
2017 年至 2020 年痤疮全身药物使用的时间趋势。
DOI: 10.1001/jamadermatol.2023.2363
发表时间: 2023
期刊: JAMA dermatology
影响因子: 10.9
作者: [Barbieri,JohnS]
通讯作者: Barbieri,JohnS
9
    Applying Item Response Theory to Improve Patient Reported Outcome Use in Dermatology Clinical Practice
    • 批准号:
      10524835
    • 项目类别:
    • 资助金额:
      $17.39万
    • 财政年份:
      2022
    • 负责人:
      John Barbieri
    • 依托单位:
    海外基金